Nicholas L. Smith

Nicholas L. Smith

Auto-generated profile, based on publicly available information

Nicholas L. Smith

University of Washington

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2010 in Circulation
Verified
Journal Article
Closed access
PDF file
NSNicholas L. Smith
Nicholas L. Smith
MCMing-Huei Chen
Ming-Huei Chen
ADAbbas Dehghan
Abbas Dehghan
DSDavid P. Strachan
David P. Strachan
SBSaonli Basu
Saonli Basu
COChristopher J. O'Donnell
Christopher J. O'Donnell
Background— Plasma levels of coagulation factors VII (FVII), VIII (FVIII), and von Willebrand factor (vWF) influence risk of hemorrhage and thrombosis. We conducted genome-wide association studies to identify new loci associated with plasma levels. Methods and Results— The setting of the study included 5 community-based studies for discovery comprising 23 608 European-ancestry participants: Atherosclerosis Risk In Communities Study, Cardiovascular Health Study, British 1958 Birth Cohort, Framingham Heart Study, and Rotterdam Study. All subjects had genome-wide single-nucleotide polymorphism (SNP) scans and at least 1 phenotype measured: FVII activity/antigen, FVIII activity, and vWF antigen. Each study used its genotype data to impute to HapMap SNPs and independently conducted association analyses of hemostasis measures using an additive genetic model. Study findings were combined by meta-analysis. Replication was conducted in 7604 participants not in the discovery cohort. For FVII, 305 SNPs exceeded the genome-wide significance threshold of 5.0×10 −8 and comprised 5 loci on 5 chromosomes: 2p23 (smallest P value 6.2×10 −24 ), 4q25 (3.6×10 −12 ), 11q12 (2.0×10 −10 ), 13q34 (9.0×10 −259 ), and 20q11.2 (5.7×10 −37 ). Loci were within or near genes, including 4 new candidate genes and F7 (13q34). For vWF, 400 SNPs exceeded the threshold and marked 8 loci on 6 chromosomes: 6q24 (1.2×10 −22 ), 8p21 (1.3×10 −16 ), 9q34 (<5.0×10 −324 ), 12p13 (1.7×10 −32 ), 12q23 (7.3×10 −10 ), 12q24.3 (3.8×10 −11 ), 14q32 (2.3×10 −10 ), and 19p13.2 (1.3×10 −9 ). All loci were within genes, including 6 new candidate genes, as well as ABO (9q34) and VWF (12p13). For FVIII, 5 loci were identified and overlapped vWF findings. Nine of the 10 new findings were replicated. Conclusions— New genetic associations were discovered outside previously known biological pathways and may point to novel prevention and treatment targets of hemostasis disorders.

3 February 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JHJaana A Hartiala
Jaana A Hartiala
YHYi Han
Yi Han
QJQiong Jia
Qiong Jia
JHJames R Hilser
James R Hilser
PHPin Huang
Pin Huang
HAHooman Allayee
Hooman Allayee
While most patients with myocardial infarction (MI) have underlying coronary atherosclerosis, not all patients with coronary artery disease (CAD) develop MI. We sought to address the hypothesis that some of the genetic factors which establish atherosclerosis may be distinct from those that predispose to vulnerable plaques and thrombus formation. We carried out a genome-wide association study for MI in the UK Biobank (n∼472 000), followed by a meta-analysis with summary statistics from the CARDIoGRAMplusC4D Consortium (n∼167 000). Multiple independent replication analyses and functional approaches were used to prioritize loci and evaluate positional candidate genes. Eight novel regions were identified for MI at the genome wide significance level, of which effect sizes at six loci were more robust for MI than for CAD without the presence of MI. Confirmatory evidence for association of a locus on chromosome 1p21.3 harbouring choline-like transporter 3 (SLC44A3) with MI in the context of CAD, but not with coronary atherosclerosis itself, was obtained in Biobank Japan (n∼165 000) and 16 independent angiography-based cohorts (n∼27 000). Follow-up analyses did not reveal association of the SLC44A3 locus with CAD risk factors, biomarkers of coagulation, other thrombotic diseases, or plasma levels of a broad array of metabolites, including choline, trimethylamine N-oxide, and betaine. However, aortic expression of SLC44A3 was increased in carriers of the MI risk allele at chromosome 1p21.3, increased in ischaemic (vs. non-diseased) coronary arteries, up-regulated in human aortic endothelial cells treated with interleukin-1β (vs. vehicle), and associated with smooth muscle cell migration in vitro. A large-scale analysis comprising ∼831 000 subjects revealed novel genetic determinants of MI and implicated SLC44A3 in the pathophysiology of vulnerable plaques.

1 April 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MGMarine Germain
Marine Germain
DCDaniel I. Chasman
Daniel I. Chasman
HHHugoline de Haan
Hugoline de Haan
WTWeihong Tang
Weihong Tang
SLSara Lindström
Sara Lindström
PMPierre-Emmanuel Morange
Pierre-Emmanuel Morange

1 June 2010 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
NSNicholas L. Smith
Nicholas L. Smith
JFJanine F. Felix
Janine F. Felix
AMAlanna Morrison
Alanna Morrison
SDSerkalem Demissie
Serkalem Demissie
NGNicole L. Glazer
Nicole L. Glazer
RVRamachandran S. Vasan
Ramachandran S. Vasan
Background—: Although genetic factors contribute to the onset of heart failure (HF), no large-scale genome-wide investigation of HF risk has been published to date. We have investigated the association of 2 478 304 single-nucleotide polymorphisms with incident HF by meta-analyzing data from 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. Methods and Results—: Eligible participants for these analyses were of European or African ancestry and free of clinical HF at baseline. Each study independently conducted genome-wide scans and imputed data to the ≈2.5 million single-nucleotide polymorphisms in HapMap. Within each study, Cox proportional hazards regression models provided age- and sex-adjusted estimates of the association between each variant and time to incident HF. Fixed-effect meta-analyses combined results for each single-nucleotide polymorphism from the 4 cohorts to produce an overall association estimate and P value. A genome-wide significance P value threshold was set a priori at 5.0×10 −7 . During a mean follow-up of 11.5 years, 2526 incident HF events (12%) occurred in 20 926 European-ancestry participants. The meta-analysis identified a genome-wide significant locus at chromosomal position 15q22 (1.4×10 −8 ), which was 58.8 kb from USP3 . Among 2895 African-ancestry participants, 466 incident HF events (16%) occurred during a mean follow-up of 13.7 years. One genome-wide significant locus was identified at 12q14 (6.7×10 −8 ), which was 6.3 kb from LRIG3 . Conclusions—: We identified 2 loci that were associated with incident HF and exceeded genome-wide significance. The findings merit replication in other community-based settings of incident HF.

7 February 2007 in JAMA
Verified
Journal Article
Open access
PDF file
NSNicholas L. Smith
Nicholas L. Smith
LHLucia A. Hindorff
Lucia A. Hindorff
SHSusan R. Heckbert
Susan R. Heckbert
RLRozenn N. Lemaitre
Rozenn N. Lemaitre
KMKristin D. Marciante
Kristin D. Marciante
BPBruce M. Psaty
Bruce M. Psaty
Deep vein thrombosis and pulmonary embolism are significant contributors to morbidity and mortality in adult women and occur at annual rates of 3 to 5 per 1000 person-years among women older than 55 years.1,2 Despite improved prophylaxis in high-risk patients, the incidence of venous thrombosis (VT) has not decreased.1

29 January 2019 in Circulation
Verified
Journal Article
Open access
PDF file
MSMaria Sabater-Lleal
Maria Sabater-Lleal
JHJennifer E. Huffman
Jennifer E. Huffman
PVPaul S. de Vries
Paul S. de Vries
JMJonathan Marten
Jonathan Marten
MMMichael A. Mastrangelo
Michael A. Mastrangelo
NSNicholas L. Smith
Nicholas L. Smith
Background: Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are associated with risk of arterial and venous thrombosis and with hemorrhagic disorders. We aimed to identify and functionally test novel genetic associations regulating plasma FVIII and VWF. Methods: We meta-analyzed genome-wide association results from 46 354 individuals of European, African, East Asian, and Hispanic ancestry. All studies performed linear regression analysis using an additive genetic model and associated ≈35 million imputed variants with natural log–transformed phenotype levels. In vitro gene silencing in cultured endothelial cells was performed for candidate genes to provide additional evidence on association and function. Two-sample Mendelian randomization analyses were applied to test the causal role of FVIII and VWF plasma levels on the risk of arterial and venous thrombotic events. Results: We identified 13 novel genome-wide significant ( P ≤2.5×10 −8 ) associations, 7 with FVIII levels ( FCHO2/TMEM171/TNPO1 , HLA , SOX17/RP1 , LINC00583/NFIB , RAB5C-KAT2A , RPL3/TAB1/SYNGR1 , and ARSA ) and 11 with VWF levels ( PDHB/PXK/KCTD6 , SLC39A8 , FCHO2/TMEM171/TNPO1 , HLA , GIMAP7/GIMAP4 , OR13C5/NIPSNAP , DAB2IP , C2CD4B , RAB5C-KAT2A , TAB1/SYNGR1 , and ARSA ), beyond 10 previously reported associations with these phenotypes. Functional validation provided further evidence of association for all loci on VWF except ARSA and DAB2IP . Mendelian randomization suggested causal effects of plasma FVIII activity levels on venous thrombosis and coronary artery disease risk and plasma VWF levels on ischemic stroke risk. Conclusions: The meta-analysis identified 13 novel genetic loci regulating FVIII and VWF plasma levels, 10 of which we validated functionally. We provide some evidence for a causal role of these proteins in thrombotic events.